Burning Rock Biotech (BNR) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to 12.26%.
- Burning Rock Biotech's EBIT Margin rose 177400.0% to 12.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.97%, marking a year-over-year increase of 633400.0%. This contributed to the annual value of 69.32% for FY2024, which is 552200.0% up from last year.
- Latest data reveals that Burning Rock Biotech reported EBIT Margin of 12.26% as of Q3 2025, which was up 177400.0% from 7.74% recorded in Q2 2025.
- Burning Rock Biotech's 5-year EBIT Margin high stood at 7.74% for Q2 2025, and its period low was 202.9% during Q2 2022.
- In the last 5 years, Burning Rock Biotech's EBIT Margin had a median value of 135.09% in 2021 and averaged 112.57%.
- As far as peak fluctuations go, Burning Rock Biotech's EBIT Margin plummeted by -904600bps in 2021, and later soared by 1101600bps in 2024.
- Quarter analysis of 5 years shows Burning Rock Biotech's EBIT Margin stood at 171.11% in 2021, then rose by 11bps to 152.88% in 2022, then increased by 10bps to 137.37% in 2023, then skyrocketed by 53bps to 65.01% in 2024, then skyrocketed by 81bps to 12.26% in 2025.
- Its EBIT Margin was 12.26% in Q3 2025, compared to 7.74% in Q2 2025 and 11.41% in Q1 2025.